EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	1159	514/367.ccls.	US-PGPUB; USPAT; FPRS; EPO; JPO; DERWENT	OR	ON	2007/08/02 12:16
L2	869	514/375.ccls.	US-PGPUB; USPAT; FPRS; EPO; JPO; DERWENT	OR	ON	2007/08/02 12:16
L3	332	548/179.ccls.	US-PGPUB; USPAT; FPRS; EPO; JPO; DERWENT	OR	ON	2007/08/02 12:16
L4	305	548/224.ccls.	US-PGPUB; USPAT; FPRS; EPO; JPO; DERWENT	OR	ON	2007/08/02 12:16
L5	2197	L1 OR L2 OR L3 OR L4	US-PGPUB; USPAT; FPRS; EPO; JPO; DERWENT	OR	ON	2007/08/02 12:17
L6	87	L5 AND PPAR	US-PGPUB; USPAT; FPRS; EPO; JPO; DERWENT	OR	ON	2007/08/02 12:17
L7	70	L5 AND PEROXISOME	US-PGPUB; USPAT; FPRS; EPO; JPO; DERWENT	OR	ON	2007/08/02 12:18
L8	93	L6 OR L7	US-PGPUB; USPAT; FPRS; EPO; JPO; DERWENT	OR	ON	2007/08/02 12:18

=>
Uploading C:\Program Files\Stnexp\Queries\10539477\4.str





chain nodes :
24 26 27 29 31 33 34 35 37 38 39 40 41 42 49 50 52 53 54 55 56
ring nodes :
1 2 3 4 5 6 7 8 10 11 12 13 14 15 18 19 20 21 22 23
ring/chain nodes :
30
chain bonds :
7-10 11-52 12-53 13-54 14-55 15-56 23-24 24-26 26-27 29-30 30-31 33-34
34-35 37-38 38-39 38-40 41-42 49-50
ring bonds :
1-2 1-5 1-6 2-3 2-8 3-4 4-5 6-7 7-8 10-11 10-15 11-12 12-13 13-14
14-15 18-19 18-23 19-20 20-21 21-22 22-23
exact/norm bonds :
1-2 1-5 1-6 2-3 2-8 3-4 4-5 6-7 7-8 7-10 11-52 12-53 13-54 14-55
15-56 23-24 24-26 26-27 29-30 30-31 33-34 34-35 37-38 38-39 38-40 41-42
49-50
normalized bonds :
10-11 10-15 11-12 12-13 13-14 14-15 18-19 18-23 19-20 20-21 21-22 22-23
isolated ring systems :
containing 10 :

G1:O,S

G2:O,S,N,SO2

```
G3:C,O,S,N

G4:[*1],[*2],[*3]

G5:O,S,N

G6:H,OH,CN,NO2,O,X,Ak,[*4]

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  10:Atom  11:Atom
12:Atom  13:Atom  14:Atom  15:Atom  18:Atom  19:Atom  20:Atom  21:Atom  22:Atom
23:Atom  24:CLASS  26:CLASS  27:CLASS  29:CLASS  30:CLASS  31:CLASS  33:CLASS
34:CLASS  35:CLASS  37:CLASS  38:CLASS  39:CLASS  40:CLASS  41:CLASS  42:CLASS
49:CLASS  50:CLASS  52:CLASS  53:CLASS  54:CLASS  55:CLASS  56:CLASS


L7      STRUCTURE UPLOADED

=> d
L7 HAS NO ANSWERS
L7              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.


=> s l7
SAMPLE SEARCH INITIATED 11:11:45 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     3493 TO ITERATE

 57.3% PROCESSED     2000 ITERATIONS                          3 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.02

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        66316 TO    73404
PROJECTED ANSWERS:               3 TO      241

L8            3 SEA SSS SAM L7

=> d scan
```

```
=> d his

     (FILE 'HOME' ENTERED AT 10:55:59 ON 02 AUG 2007)

     FILE 'REGISTRY' ENTERED AT 10:56:05 ON 02 AUG 2007
L1             STRUCTURE UPLOADED
L2          50 S L1
L3             STRUCTURE UPLOADED
L4          50 S L3
L5             STRUCTURE UPLOADED
L6          38 S L5
L7             STRUCTURE UPLOADED
L8           3 S L7

=> s l7 full
FULL SEARCH INITIATED 11:12:13 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED ✓    69453 TO ITERATE

100.0% PROCESSED✓  69453 ITERATIONS                          86 ANSWERS
SEARCH TIME: 00.00.03

L9          86 SEA SSS FUL L7

=> fil caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                               183.80     184.01

FILE 'CAPLUS' ENTERED AT 11:12:24 ON 02 AUG 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 2 Aug 2007  VOL 147 ISS 6
FILE LAST UPDATED: 1 Aug 2007  (20070801/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s 19
L10         16 L9

=> d ibib abs hitstr 1-16
```

L10 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:164361 CAPLUS
DOCUMENT NUMBER: 144:254153
TITLE: Preparation of benzotriazoles as modulators of PPAR for use in therapy
INVENTOR(S): Zhu, Yan; Ma, Jingyuan; Cheng, Peng; Zhao, Zuchun; Gregoire, Francine M.; Rakhmanova, Vera A.
PATENT ASSIGNEE(S): Metabolex, Inc., USA
SOURCE: PCT Int. Appl., 163 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006020916	A2	20060223	WO 2005-US28822	20050812
WO 2006020916	A3	20060601		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 2006058301	A1	20060316	US 2005-202963	20050811
EP 1776111	A2	20070425	EP 2005-785499	20050812
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				

PRIORITY APPLN. INFO.:	US 2004-601305P	P	20040813
	US 2005-202963	A	20050811
	WO 2005-US28822	W	20050812

OTHER SOURCE(S): MARPAT 144:254153
GI

L10 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



I

AB The present invention is directed to certain novel compds. represented by Z-K-Ar1-L-Ar2-R1 (wherein Ar1 = (un)substituted monocyclic or bicyclic aromatic ring; Ar2 = (un)substituted 6-membered monocyclic aromatic ring; K and L = linking groups; R1 = a heterocyclic ring) and pharmaceutically acceptable salts, solvates, hydrates and prodrugs thereof. The present invention is also directed to methods of making and using such compds. and pharmaceutical compns. containing such compds. to treat or control a number of diseases mediated by PPAR such as glucose metabolism, lipid metabolism and insulin secretion, specifically Type 2 diabetes, hyperinsulinemia, hyperlipidemia, hyperuricemia, hypercholesteremia, atherosclerosis, one or more risk factors for cardiovascular disease, Syndrome X, hypertriglyceridemia, hyperglycemia, obesity and eating disorders. For example, I was prepared from [4-(3-bromo-propylsulfanyl)-2-methylphenoxy]acetic acid Et ester and 2-benzooxazol-2-yl-4-bromophenol followed by hydrolysis of the ester formed. In a PPARs transactivation assay, I was a modulator of PPARα, PPARδ, and PPARγ having an EC50 ≤ 10μM.
IT 877156-77-9P, [[4-[[3-[2-(Benzothiazol-2-yl)-4-chlorophenoxy]propyl]sulfanyl]-2-methylphenyl]oxy]acetic acid
877156-78-0P, [[4-[[3-[2-(Benzoxazol-2-yl)-4-bromophenoxy]propyl]sulfanyl]-2-methylphenyl]oxy]acetic acid
877157-07-8P, [[4-[[3-[[3-(Benzoxazol-2-yl)phenyl]oxy]propyl]sulfanyl]-2-methylphenyl]oxy]acetic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of benzotriazoles as modulators of PPAR for use in therapy)
RN 877156-77-9 CAPLUS
CN Acetic acid, [4-[[3-[2-(2-benzothiazolyl)-4-chlorophenoxy]propyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

L10 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 877156-78-0 CAPLUS
CN Acetic acid, [4-[[3-[2-(2-benzoxazolyl)-4-bromophenoxy]propyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 877157-07-8 CAPLUS
CN Acetic acid, [4-[[3-[3-(2-benzoxazolyl)phenoxy]propyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



L10 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:1333661 CAPLUS
DOCUMENT NUMBER: 144:135216
TITLE: Small molecule pharmaceutical preparations for treating dysmenorrhea and severe rheumatic arthritis pain
INVENTOR(S): Sun, Tianming; Sun, Meng
PATENT ASSIGNEE(S): Peop. Rep. China
SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 16 pp.
CODEN: CNXXEV
DOCUMENT TYPE: Patent
LANGUAGE: Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1600370	A	20050330	CN 2003-10103027	20031031

PRIORITY APPLN. INFO.:	CN 2003-10103027		20031031

AB This invention relates to synthetic small mol. pharmaceutical prepns. for relieving spasmodic dysmenorrhea and severe pain caused by rheumatic arthritis. The pharmaceutical prepns. contain three effective components including nonsteroidal anti-inflammatory drug, antidepressant, and effective component for alleviating stomach discomfort and diarrhea induced by the medicine.
IT 873201-62-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(small mol. pharmaceutical prepns. for treating dysmenorrhea and severe rheumatic arthritis pain)
RN 873201-62-8 CAPLUS
CN 5-Benzoxazoleacetamide, 2-(4-fluorophenyl)-N,α-dimethyl-N-[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 3 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:1092645 CAPLUS
DOCUMENT NUMBER: 144:264067
TITLE: Heterocyclic reactive mesogens: synthesis, characterisation and mesomorphic behaviour
AUTHOR(S): Aldred, Matthew; Vlachos, Panos; Dong, Dewen; Kitney, Stuart; Chung Tsoi, W.; O'Neill, Mary; Kelly, Stephen
CORPORATE SOURCE: Department of Chemistry, University of Hull, Hull, HU6
7RX, Peop. Rep. China
SOURCE: Liquid Crystals (2005), 32(8), 951-965
CODEN: LICRE6; ISSN: 0267-8292
PUBLISHER: Taylor & Francis Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Novel heterocyclic and photopolymerizable liquid crystalline materials (reactive mesogens) with smectic phases were synthesized and characterized. A selection of heterocyclic rings, such as benzothiazole, benzothiadiazole and pyrimidine, was incorporated into the aromatic core to control the electrochem./luminescence properties and the structural geometry. Particular emphasis is focused on structure-property relations, in which the variation of mol. structure and its subsequent effect on the liquid crystalline transition temps. were studied.
IT 877207-68-6P 877207-69-7P
RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); SPN (Synthetic preparation); PREP (Preparation); PROC (Process)
(preparation and liquid crystal properties of)
RN 877207-68-6 CAPLUS
CN Hexanoic acid, 6,6'-[2,6-benzothiazolediylbis(4,1-phenyleneoxy)]bis-, bis(1-ethenyl-2-propenyl) ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 877207-69-7 CAPLUS
CN Undecanoic acid, 11,11'-[2,6-benzothiazolediylbis(4,1-phenyleneoxy)]bis-,

L10 ANSWER 3 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
bis(1-ethenyl-2-propenyl) ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



REFERENCE COUNT: 55 THERE ARE 55 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:995905 CAPLUS
DOCUMENT NUMBER: 142:6415
TITLE: Preparation of indoleacetic acids for the treatment of diabetes and related diseases.
INVENTOR(S): Ma, Xin; Cantin, Louis-David; Choi, Soongyu; Clark, Roger; Hentemann, Martin; Rudolph, Joachim; Lavoie, Rico; Zhang, Zhonghua
PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA
SOURCE: PCT Int. Appl., 142 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004098498	A2	20041118	WO 2004-US12959	20040428
WO 2004098498	A3	20050728		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2523245	A1	20041118	CA 2004-2523245	20040428
EP 1620088	A2	20060201	EP 2004-750750	20040428
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
JP 2006524709	T	20061102	JP 2006-513366	20040428
US 2006264486	A1	20061123	US 2005-555024	20051026
PRIORITY APPLN. INFO.:			US 2003-466143P	P 20030428
			WO 2004-US12959	W 20040428

OTHER SOURCE(S): MARPAT 142:6415
GI



AB Title compds. [I; R1 = H, alkyl, PhCH2; R2, R3 = H, alkyl; Y = O, NR5; R5 = H, alkyl, cycloalkylalkyl; n = 2-4; Ar = (substituted) Ph, heteroaryl],

L10 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
were prepd. for the treatment of diseases such as diabetes and metabolic syndrome X (no data). Thus, 1-(2-bromoethoxy)-4-ethyl-2-methoxybenzene (prepn. given), Me 2-(5-hydroxyindol-1-yl)propionate (prepn. given) and Cs2CO3 were heated at 140° in DMF for 3 h followed by addn. of HCl to pH 2 to give 8% 2-[5-[2-(4-ethyl-2-methoxyphenoxy)ethoxy]indol-1-yl]propionic acid.
IT 796098-23-2P 796098-41-4P 796098-50-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; preparation of indoleacetic acids for the treatment of diabetes and related diseases)
RN 796098-23-2 CAPLUS
CN 1H-Indole-1-acetic acid, α,3-dimethyl-5-[3-[2-propyl-4-(4,5,6,7-tetrahydro-2-benzoxazolyl)phenoxy]propoxy]- (9CI) (CA INDEX NAME)



RN 796098-41-4 CAPLUS
CN 1H-Indole-1-acetic acid, α-methyl-5-[3-[4-(4,5,6,7-tetrahydro-2-benzothiazolyl)phenoxy]propoxy]- (9CI) (CA INDEX NAME)



RN 796098-50-5 CAPLUS
CN 1H-Indole-1-acetic acid, α,3-dimethyl-5-[3-[2-propyl-4-(4,5,6,7-tetrahydro-2-benzothiazolyl)phenoxy]propoxy]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L10 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



IT 796099-69-9P 796099-71-3P
RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of indoleacetic acids for the treatment of diabetes and related diseases)
RN 796099-69-9 CAPLUS
CN 1H-Indole-1-acetic acid, α-methyl-5-[3-[4-(4,5,6,7-tetrahydro-2-benzothiazolyl)phenoxy]propoxy]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 796099-71-3 CAPLUS
CN 1H-Indole-1-acetic acid, α-methyl-5-[3-[4-(4,5,6,7-tetrahydro-2-benzothiazolyl)phenoxy]propoxy]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 796100-92-0P 796100-96-4P 796101-03-6P
796101-16-1P 796101-20-7P 796101-57-0P
796101-64-9P 796101-77-4P 796101-85-4P

L10 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
796101-96-7P 796101-99-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of indoleacetic acids for the treatment of diabetes and related diseases)
RN 796100-92-0 CAPLUS
CN 1H-Indole-1-acetic acid, α-methyl-5-[3-[4-(4,5,6,7-tetrahydro-2-benzoxazolyl)phenoxy]propoxy]- (9CI) (CA INDEX NAME)



RN 796100-96-4 CAPLUS
CN 1H-Indole-1-acetic acid, 5-[3-[2-methoxy-4-(4,5,6,7-tetrahydro-2-benzoxazolyl)phenoxy]propoxy]-α-methyl- (9CI) (CA INDEX NAME)



RN 796101-03-6 CAPLUS
CN 1H-Indole-1-acetic acid, α-methyl-5-[3-[2-propyl-4-(4,5,6,7-tetrahydro-2-benzoxazolyl)phenoxy]propoxy]- (9CI) (CA INDEX NAME)



RN 796101-16-1 CAPLUS
CN 1H-Indole-1-acetic acid, α,3-dimethyl-5-[3-[4-(4,5,6,7-tetrahydro-2-

L10 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
benzoxazolyl)phenoxy]propoxy]- (9CI) (CA INDEX NAME)



RN 796101-20-7 CAPLUS
CN 1H-Indole-1-acetic acid, 5-[3-[2-methoxy-4-(4,5,6,7-tetrahydro-2-benzoxazolyl)phenoxy]propoxy]-α,3-dimethyl- (9CI) (CA INDEX NAME)



RN 796101-57-0 CAPLUS
CN 1H-Indole-1-acetic acid, 5-[3-[2-methoxy-4-(4,5,6,7-tetrahydro-2-benzothiazolyl)phenoxy]propoxy]-α-methyl- (9CI) (CA INDEX NAME)



RN 796101-64-9 CAPLUS
CN 1H-Indole-1-acetic acid, α-methyl-5-[3-[2-propyl-4-(4,5,6,7-tetrahydro-2-benzothiazolyl)phenoxy]propoxy]- (9CI) (CA INDEX NAME)

L10 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 796101-77-4 CAPLUS
CN 1H-Indole-1-acetic acid, α,3-dimethyl-5-[3-[4-(4,5,6,7-tetrahydro-2-benzothiazolyl)phenoxy]propoxy]- (9CI) (CA INDEX NAME)



RN 796101-85-4 CAPLUS
CN 1H-Indole-1-acetic acid, 5-[3-[2-methoxy-4-(4,5,6,7-tetrahydro-2-benzothiazolyl)phenoxy]propoxy]-α,3-dimethyl- (9CI) (CA INDEX NAME)



RN 796101-96-7 CAPLUS
CN 1H-Indole-1-acetic acid, α,3-dimethyl-5-[3-[2-propyl-4-(4,5,6,7-tetrahydro-2-benzothiazolyl)phenoxy]propoxy]- (9CI) (CA INDEX NAME)

L10 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 796101-99-0 CAPLUS
CN 1H-Indole-1-acetic acid, α,3-dimethyl-5-[3-[2-propyl-4-(4,5,6,7-tetrahydro-2-benzothiazolyl)phenoxy]propoxy]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



X

L10 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:606439 CAPLUS
DOCUMENT NUMBER: 141:157107
TITLE: Preparation of fused heterocyclic derivatives as PPAR modulators for treatment of diabetes mellitus, syndrome X, and related disorders
INVENTOR(S): Conner, Scott Eugene; Mantlo, Nathan Bryan; Zhu, Guoxin
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 294 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

Instant App.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004063155	A1	20040729	WO 2003-US39120	20031231
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2509202	A1	20040729	CA 2003-2509202	20031231
AU 2003296405	A1	20040810	AU 2003-296405	20031231
EP 1585726	A1	20051019	EP 2003-815196	20031231
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, BG, CZ, EE, HU, SK				
JP 2006516254	T	20060629	JP 2004-566526	20031231
US 2006205744	A1	20060914	US 2005-539477	20050621
PRIORITY APPLN. INFO.:			US 2003-438540P P	20030106
			US 2003-438541P P	20030106
			WO 2003-US39120 W	20031231

12/31/03

1/6/03

OTHER SOURCE(S): MARPAT 141:157107
GI

L10 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



I



II

AB Title compds. I [wherein R1 = H, (un)substituted alkyl, alkenyl, (hetero)aryl(alkyl), arylheteroalkyl, cycloalkylaryl(alkyl); R2 = absent, (hetero)alkyl; R8 = H, alkyl, alkylenyl, halo; R9 = H, (un)substituted alkyl, alkylenyl, halo, aryl(alkyl), heteroaryl, allyl, alkoxy, alkylthio, etc.; R10, R11 = independently H, OH, CN, NO2, halo, oxo, (un)substituted (halo)alkyl, alkoxy, cycloalkyl, (hetero)aryl(alkyl), cycloalkylaryl(alkyl), aryloxy, acyl, carboxy, amino, sulfamoyl, etc.; R32 = bond, H, halo, (halo)alkyl, alkyloxo; AL = fused carbocyclic, pyridinyl, pyrimidinyl, Ph; B = S, O, CH2, NH; E = (un)substituted carboxy(methyl), tetrazolyl(methyl), nitriloalkyl, carboxamido(methyl), sulfonamido(methyl); U = (un)substituted aliphatic linker wherein one C of the linker is optionally replaced with O, NH, or S; X = bond, O, S, SO2, NH; Y = bond, CH2, NH; Z = N, CH, with the proviso that when B = CH2, then Z = N; or stereoisomers, pharmaceutically acceptable salts, solvates, and hydrates thereof] were prepared as peroxisome proliferator activated receptor (PPAR) modulators (no data). For example, (4-mercapto-2-methylphenoxy)acetic acid Me ester was coupled with toluene-4-sulfonic acid 2-(4-trifluoromethylphenyl)-5,6-dihydro-4H-cyclopentathiazol-4-ylmethyl ester in the presence of Cs2CO3 in anhydrous acetonitrile to give the [[(cyclopentathiazolylmethyl)sulfanyl]phenoxy]acetate (45%), which was saponified with LiOH in THF to afford II (quant.). I and their pharmaceutical compns. are expected to be effective in treating and preventing Syndrome X, Type II diabetes, cardiovascular disorders, inflammatory conditions, and other disorders (no data).

IT 729591-17-7P, [2-Methyl-4-[[1-[2-(4-trifluoromethylphenyl)benzothiazol-4-yl]ethyl]sulfanyl]phenoxy]acetic acid 729591-18-8P, 3-[2-Methyl-4-[[1-[2-(4-trifluoromethylphenyl)benzothiazol-4-yl]ethyl]sulfanyl]phenyl]propionic acid 729591-35-9P, 2-Methyl-4-[[2-[2-(4-trifluoromethylphenyl)benzothiazol-4-yl]ethyl]sulfanyl]phenoxyacetic acid 729591-40-6P, 3-[2-Methyl-4-[[2-[2-(4-trifluoromethylphenyl)benzothiazol-4-yl]ethyl]sulfanyl]phenyl]propionic acid 729591-41-7P, 2-Ethyl-4-[[2-[2-(4-trifluoromethylphenyl)benzothiazol-4-yl]ethyl]sulfanyl]phenoxyacetic acid 729591-53-1P, 3-[2-Methyl-4-[[2-[2-(4-trifluoromethylphenyl)benzothiazol-5-yl]ethyl]sulfanyl]phenyl]propionic acid 729591-66-6P, 2-Methyl-4-[[1-[2-(4-trifluoromethylphenyl)benzothiazol-6-yl]ethyl]sulfanyl]phenoxyacetic acid 729591-70-2P, 3-[2-Methyl-4-[[1-[2-(4-trifluoromethylphenyl)benzothiazol-6-yl]ethyl]sulfanyl]phenyl]propionic acid 729591-71-3P, 3-[2-Methyl-4-[[1-[2-(4-trifluoromethylphenyl)benzothiazol-6-yl]propyl]sulfanyl]phenyl]propionic acid 729591-88-2P, 2-Methyl-4-[[1-methyl-1-[2-(4-trifluoromethylphenyl)benzoxazol-7-yl]ethyl]sulfanyl]phenoxyacetic acid 729591-92-8P, 3-[2-Methyl-4-[[1-methyl-1-[2-(4-trifluoromethylphenyl)benzoxazol-7-yl]ethyl]sulfanyl]phenyl]propionic acid 729591-93-9P, 2-Ethyl-4-[[1-methyl-1-[2-(4-trifluoromethylphenyl)benzoxazol-7-yl]ethyl]sulfanyl]phenoxyacetic acid 729591-95-1P, 2-Methyl-4-[[1-[2-(4-trifluoromethylphenyl)benzoxazol-7-yl]ethyl]sulfanyl]phenoxyacetic acid 729591-98-4P, 3-[2-Methyl-4-[[1-[2-(4-trifluoromethylphenyl)benzoxazol-7-yl]ethyl]sulfanyl]phenyl]propionic acid 729591-99-5P, 2-Ethyl-4-[[1-[2-(4-trifluoromethylphenyl)benzoxazol-7-yl]ethyl]sulfanyl]phenoxyacetic acid 729592-01-2P, 3-[2-Methyl-4-[1-[2-(4-trifluoromethylphenyl)benzoxazol-7-yl]ethoxy]phenyl]propionic acid 729592-02-3P, 3-[2-Ethyl-4-[1-[2-(4-trifluoromethylphenyl)benzoxazol-7-yl]ethoxy]phenyl]propionic acid 729592-56-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(PPAR modulator; prepn. of fused heterocyclic derivs. as PPAR modulators for treatment of diabetes mellitus, syndrome X, and other disorders)

RN 729591-17-7 CAPLUS
CN Acetic acid, [2-methyl-4-[[1-[2-[4-(trifluoromethyl)phenyl]-4-benzothiazolyl]ethyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



Y-E-A

x

u

RN 729591-18-8 CAPLUS
CN Benzenepropanoic acid, 2-methyl-4-[[1-[2-[4-(trifluoromethyl)phenyl]-4-benzothiazolyl]ethyl]thio]- (9CI) (CA INDEX NAME)

L10 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 729591-35-9 CAPLUS
CN Acetic acid, [2-methyl-4-[[2-[2-[4-(trifluoromethyl)phenyl]-4-benzothiazolyl]ethyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 729591-40-6 CAPLUS
CN Benzenepropanoic acid, 2-methyl-4-[[2-[2-[4-(trifluoromethyl)phenyl]-4-benzothiazolyl]ethyl]thio]- (9CI) (CA INDEX NAME)

L10 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 729591-66-6 CAPLUS
CN Acetic acid, [2-methyl-4-[[1-[2-[4-(trifluoromethyl)phenyl]-6-benzothiazolyl]ethyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 729591-70-2 CAPLUS
CN Benzenepropanoic acid, 2-methyl-4-[[1-[2-[4-(trifluoromethyl)phenyl]-6-benzothiazolyl]ethyl]thio]- (9CI) (CA INDEX NAME)



RN 729591-71-3 CAPLUS
CN Benzenepropanoic acid, 2-methyl-4-[[1-[2-[4-(trifluoromethyl)phenyl]-6-benzothiazolyl]propyl]thio]- (9CI) (CA INDEX NAME)

RN 729591-88-2 CAPLUS
CN Acetic acid, [2-methyl-4-[[1-methyl-1-[2-[4-(trifluoromethyl)phenyl]-7-benzoxazolyl]ethyl]thio]phenoxy]- (9CI) (CA INDEX NAME)

L10 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 729591-41-7 CAPLUS
CN Acetic acid, [2-ethyl-4-[[2-[2-[4-(trifluoromethyl)phenyl]-4-benzothiazolyl]ethyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 729591-53-1 CAPLUS
CN Benzenepropanoic acid, 2-methyl-4-[[2-[2-[4-(trifluoromethyl)phenyl]-5-benzothiazolyl]ethyl]thio]- (9CI) (CA INDEX NAME)



L10 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 729591-92-8 CAPLUS
CN Benzenepropanoic acid, 2-methyl-4-[[1-methyl-1-[2-[4-(trifluoromethyl)phenyl]-7-benzoxazolyl]ethyl]thio]- (9CI) (CA INDEX NAME)



RN 729591-93-9 CAPLUS
CN Acetic acid, [2-ethyl-4-[[1-methyl-1-[2-[4-(trifluoromethyl)phenyl]-7-benzoxazolyl]ethyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



L10 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 729591-95-1 CAPLUS
CN Acetic acid, [2-methyl-4-[[1-[2-[4-(trifluoromethyl)phenyl]-7-benzoxazolyl]ethyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 729591-98-4 CAPLUS
CN Benzenepropanoic acid, 2-methyl-4-[[1-[2-[4-(trifluoromethyl)phenyl]-7-benzoxazolyl]ethyl]thio]- (9CI) (CA INDEX NAME)



RN 729591-99-5 CAPLUS
CN Acetic acid, [2-ethyl-4-[[1-[2-[4-(trifluoromethyl)phenyl]-7-benzoxazolyl]ethyl]thio]phenoxy]- (9CI) (CA INDEX NAME)

L10 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 729592-56-7 CAPLUS
CN Benzenepropanoic acid, 2-methyl-4-[2-[2-[4-(trifluoromethyl)phenyl]-4-benzoxazolyl]ethoxy]- (9CI) (CA INDEX NAME)



IT 729591-39-3P, Ethyl [2-Methyl-4-[[2-[2-(4-trifluoromethylphenyl)benzothiazol-4-yl]ethyl]sulfanyl]phenoxy]acetate
729591-57-5P, Methyl 3-[2-Methyl-4-[[2-[2-(4-trifluoromethylphenyl)benzothiazol-5-yl]ethyl]sulfanyl]phenyl]propionate
729591-69-9P, Ethyl [2-Methyl-4-[[1-[2-(4-trifluoromethylphenyl)benzothiazol-6-yl]ethyl]sulfanyl]phenoxy]acetate
729591-73-5P, Methyl 3-[2-Methyl-4-[[1-[2-(4-trifluoromethylphenyl)benzothiazol-6-yl]propyl]sulfanyl]phenyl]propionate
729591-91-7P, Ethyl [2-Methyl-4-[[1-methyl-1-[2-(4-trifluoromethylphenyl)benzoxazol-7-yl]ethyl]sulfanyl]phenoxy]acetate
729591-97-3P, Ethyl [2-Methyl-4-[[1-[2-(4-trifluoromethylphenyl)benzoxazol-7-yl]ethyl]sulfanyl]phenoxy]acetate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of fused heterocyclic derivs. as PPAR modulators
for treatment of diabetes mellitus, syndrome X, and other disorders)

RN 729591-39-3 CAPLUS
CN Acetic acid, [2-methyl-4-[[2-[2-[4-(trifluoromethyl)phenyl]-4-

L10 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 729592-01-2 CAPLUS
CN Benzenepropanoic acid, 2-methyl-4-[1-[2-[4-(trifluoromethyl)phenyl]-7-benzoxazolyl]ethoxy]- (9CI) (CA INDEX NAME)



RN 729592-02-3 CAPLUS
CN Benzenepropanoic acid, 2-ethyl-4-[1-[2-[4-(trifluoromethyl)phenyl]-7-benzoxazolyl]ethoxy]- (9CI) (CA INDEX NAME)

L10 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
benzothiazolyl]ethyl]thio]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 729591-57-5 CAPLUS
CN Benzenepropanoic acid, 2-methyl-4-[[2-[2-[4-(trifluoromethyl)phenyl]-5-benzothiazolyl]ethyl]thio]-, methyl ester (9CI) (CA INDEX NAME)



RN 729591-69-9 CAPLUS
CN Acetic acid, [2-methyl-4-[[1-[2-[4-(trifluoromethyl)phenyl]-6-benzothiazolyl]ethyl]thio]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 729591-73-5 CAPLUS
CN Benzenepropanoic acid, 2-methyl-4-[[1-[2-[4-(trifluoromethyl)phenyl]-6-benzothiazolyl]propyl]thio]-, methyl ester (9CI) (CA INDEX NAME)

L10 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 729591-91-7 CAPLUS
CN Acetic acid, [2-methyl-4-[[1-methyl-1-[2-[4-(trifluoromethyl)phenyl]-7-benzoxazolyl]ethyl]thio]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 729591-97-3 CAPLUS
CN Acetic acid, [2-methyl-4-[[1-[2-[4-(trifluoromethyl)phenyl]-7-benzoxazolyl]ethyl]thio]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)

L10 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L10 ANSWER 6 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:159428 CAPLUS
DOCUMENT NUMBER: 140:200659
TITLE: Polybenzoxazoles with low elastic modulus, their precursors, and optical waveguides using them
INVENTOR(S): Tominaga, Yumiko
PATENT ASSIGNEE(S): Sumitomo Bakelite Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 32 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2004059761	A	20040226	JP 2002-220848	20020730
PRIORITY APPLN. INFO.:			JP 2002-220848	20020730

AB The precursors comprise [CONHY(OR1)(OR2)NHCOX]n [n = 2-1000; X = C6H4O2C(CF2)iCO2C6H4, divalent organic group; Y = C6H3O2C(CF2)iCO2C6H3, tetravalent organic group; X and/or Y = the diester group; R1, R2 = H, monovalent organic group; i = 1-10]. Thus, bis(4-amino-3-hydroxyphenyl) perfluoropentanedioate was polymerized with isophthaloyl chloride to give a polybenzoxazole precursor, which was applied on a glass plate and heated to give a polybenzoxazole film showing relative permittivity 2.3, 5% weight loss temperature 532°, elastic modulus 3 GPa, and water absorption 0.1%. Optical waveguides showing low optical loss were manufactured using the polybenzoxazoles as clad and core layers.

IT 660832-57-5P 660832-61-1P 660832-72-4P
RL: IMF (Industrial manufacture); PRP (Properties); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)
(manufacture of polybenzoxazoles with low elastic modulus, their precursors, and optical waveguides using them)

RN 660832-57-5 CAPLUS
CN Poly[2,6-benzoxazolediyloxy(2,2,3,3,4,4-hexafluoro-1,5-dioxo-1,5-pentanediyl)oxy-6,2-benzoxazolediyl-1,4-phenyleneoxy-1,4-phenylene] (9CI) (CA INDEX NAME)

PAGE 1-A



L10 ANSWER 6 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B



RN 660832-61-1 CAPLUS
CN Poly(6,2-benzoxazolediyl-1,4-phenylene(1-methylethylidene)-1,4-phenylene-2,6-benzoxazolediyloxy(2,2,3,3,4,4,5,5,6,6,7,7-dodecafluoro-1,8-dioxo-1,8-octanediyl)oxy] (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

RN 660832-72-4 CAPLUS
CN Poly[2,6-benzoxazolediyloxy(2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,11,11-eicosafluoro-1,12-dioxo-1,12-dodecanediyl)oxy-6,2-benzoxazolediyl-1;4-phenyleneoxy-1,4-phenyleneoxy-1,4-phenylene] (9CI) (CA INDEX NAME)

L10 ANSWER 6 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



L10 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:633643 CAPLUS
DOCUMENT NUMBER: 139:180343
TITLE: Preparation of aromatic amino acid derivatives as anticancer agents
INVENTOR(S): Endo, Hitoshi; Kanai, Yoshikatsu; Tsujihara, Kenji; Saito, Kunio
PATENT ASSIGNEE(S): Japan
SOURCE: PCT Int. Appl., 124 pp.
CODEN: PIXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003066574	A1	20030814	WO 2003-JP1081	20030203
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2475434	A1	20030814	CA 2003-2475434	20030203
AU 2003208105	A1	20030902	AU 2003-208105	20030203
EP 1481965	A1	20041201	EP 2003-703151	20030203
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2005119256	A1	20050602	US 2003-503125	20030203
CN 1630632	A	20050622	CN 2003-803549	20030203
PRIORITY APPLN. INFO.:			JP 2002-31216 A	20020207
			WO 2003-JP1081 W	20030203

OTHER SOURCE(S): MARPAT 139:180343
GI



I

Close art

AB Aromatic amino acid derivs. represented by the following general formula (I)

L10 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

or pharmacol. acceptable salts thereof [wherein R1 represents hydrogen or an amino-protecting group; R2 represents hydrogen, alkylaralkyl or aryl; R3 represents (1) halogeno, (2) aroylamino, (3) Ph substituted by lower alkyl, Ph, phenoxy, etc., (4) naphthyl or tetrahydronaphthyl optionally substituted by hydroxy, lower alkoxy or di(lower alkyl)amino, (5) an N-, O- and/or S-contg. unsatd. monocyclic heterocycle group substituted by lower alkyl, Ph, naphthyl or tetrahydroquinolyl, or (6) an N-, O- and/or S-contg. fused heterocycle group, which may be unsatd. or partly satd., optionally substituted by oxo, carboxy, amino, lower alkyl, etc.; X represents halogeno, alkyl or alkoxy; Y represents oxygen or nitrogen; p is 0 or 1; m is 0, 1 or 2; and n is an integer of from 0 to 5] are prepd. These compds. inhibit a transporter (LAT1) of essential amino acids which are one of the main nutrients for cancer cells and induce depletion of the essential amino acids in the cancer cells, thereby inhibit the proliferation of the cancer cells. Thus, 0.2 mL pyridine was added to a suspension of N-trifluoroacetyl-3-hydroxy-L-phenylalanine Et ester 159, 2-naphthaleneboronic acid 186, mol. sieve 4A 204, and Cu(OAc)2 153 mg in 7 mL CH2Cl2, stirred at room temp. for 16 h in air to give, after workup and silica gel chromatog., 89% N-trifluoroacetyl-3-(2-naphthyloxy)-L-phenylalanine Et ester (II). 0.5 N aq. NaOH was added to a soln. of II (94 mg) in 2 mL THF at 5°, stirred at 5° for 69 h, acidified with 1 N aq. HCl to pH 3-4, and filtered to give 78% 3-(2-naphthyloxy)-L-phenylalanine (III). In an assay for a LAT1 inhibitory activity, III and 3-[3-(6-dimethylaminopyridyl)phenoxy]-L-phenylalanine in vitro showed IC50 of 0.1 and 0.01 μg/mL, resp., for inhibiting the uptake of [14C]-L-tyrosine by human prostatic cancer T24 cells.

IT 579524-13-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aromatic amino acid derivs. as anticancer agents for inhibiting proliferation of cancer cells by inhibiting essential amino acid transporter (LAT1))

RN 579524-13-3 CAPLUS
CN L-Tyrosine, 3,5-dichloro-O-[2-(2-phenyl-7-benzoxazolyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

IT 579526-14-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of aromatic amino acid derivs. as anticancer agents for inhibiting proliferation of cancer cells by inhibiting essential amino acid transporter (LAT1))

RN 579526-14-0 CAPLUS
CN L-Tyrosine, 3,5-dichloro-O-[2-(2-phenyl-7-benzoxazolyl)ethyl]-N-(trifluoroacetyl)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

$E = C(R^3R^4) - A$

L10 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:413899 CAPLUS
DOCUMENT NUMBER: 139:7388
TITLE: Liquid crystal alignment layer, display, reactive mesogens and polymers formed from the reactive mesogen
INVENTOR(S): O'Neill, Mary; Kelly, Stephen Malcolm; Contoret, Adam Edward Alexander; Richards, Gary James; Coates, David
PATENT ASSIGNEE(S): UK
SOURCE: U.S. Pat. Appl. Publ., 39 pp., Cont.-in-part of U.S. Ser. No. 898,749.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003099785	A1	20030529	US 2002-187396	20020701
US 7118787	B2	20061010		
US 2003021913	A1	20030130	US 2001-898749	20010703
PRIORITY APPLN. INFO.:			GB 2001-15987 A	20010629
			US 2001-898749 A2	20010703
			WO 1999-GB4287 W	19991216

AB A liquid crystal alignment layer comprises an alignment layer, and chemical bound to the alignment layer, a transport material, for use in displays for electronic apparatus
IT 532984-00-2P 532984-02-4P
RL: IMF (Industrial manufacture); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)
(alignment layer; liquid crystal alignment layer for displays and electroluminescent devices)
RN 532984-00-2 CAPLUS
CN Benzoic acid, 4-[[6-[(2-methyl-1-oxo-2-propenyl)oxy]hexyl]oxy]-, 4-(2-benzothiazolyl)-2,6-dimethoxyphenyl ester, polymer with 2-oxo-2H-1-benzopyran-7-yl 4-[[6-[(2-methyl-1-oxo-2-propenyl)oxy]hexyl]oxy]benzoate (9CI) (CA INDEX NAME)

CM 1

CRN 532983-99-6
CMF C32 H33 N O7 S

L10 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



CM 2

CRN 177856-55-2
CMF C26 H26 O7



RN 532984-02-4 CAPLUS
CN Benzoic acid, 4-[[6-[(2-methyl-1-oxo-2-propenyl)oxy]hexyl]oxy]-, 4-[6-(4-nonylphenyl)-2-benzothiazolyl]phenyl ester, polymer with 2-oxo-2H-1-benzopyran-7-yl 4-[[6-[(2-methyl-1-oxo-2-propenyl)oxy]hexyl]oxy]benzoate (9CI) (CA INDEX NAME)

CM 1

CRN 532984-01-3
CMF C45 H51 N O5 S



CM 2

CRN 177856-55-2
CMF C26 H26 O7



REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:154391 CAPLUS
DOCUMENT NUMBER: 138:187634
TITLE: Preparation of 2-benzyltetrahydrofuran-2-carboxylic acid derivatives as PPAR agonists for treatment of hyperglycemia, hyperlipemia, and inflammatory diseases
INVENTOR(S): Clark, Richard; Matsuura, Fumiyoshi; Emori, Eita; Shinoda, Masanobu; Kasai, Shunji; Yoshitomi, Hideki; Yamazaki, Kazuto; Inoue, Takashi; Miyashita, Sadakazu; Hihara, Taro
PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan
SOURCE: PCT Int. Appl., 220 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003016265	A1	20030227	WO 2002-JP8325	20020816
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002325535	A1	20030303	AU 2002-325535	20020816
EP 1452521	A1	20040901	EP 2002-758850	20020816
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
US 2005014833	A1	20050120	US 2004-486396	20040211
PRIORITY APPLN. INFO.:			JP 2001-247540 A	20010817
			WO 2002-JP8325 W	20020816

OTHER SOURCE(S): MARPAT 138:187634
GI

close art

L10 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



I



II

AB The title compds. I [wherein m, n, and p = independently 0-4; R1-R6 = independently H, OH, CN, halo, NR7R8, (un)substituted alkyl(thio), alkoxy, HO-alkyl(thio), HO-alkoxy, aminoalkyl(thio), halo-alkyl(thio), halo-alkoxy, alkoxyalkyl(thio), alkoxyalkoxy, cycloalkyl(oxy), cycloalkylalkyloxy, cycloalkylthio, alkenyl(oxy), alkenylthio, alkynyl(oxy), alkynylthio, aryl(oxy), arylthio, alkylaryl(oxy), alkylarylthio, aralkyl(oxy), or aralkylthio; R7 and R8 = independently H, CN, CHO, (un)substituted (amino)alkyl, HO-alkyl, halo-alkyl, alkoxyalkyl, cycloalkyl, alkenyl, alkynyl, (alkyl)aryl, aralkyl, acyl, or alkoxy-CO; A1 and A2 = independently a single bond, O, S, SO, SO2, (un)substituted amino, or alkenylenyl; L, M, and T = independently a single bond, (un)substituted alkylenyl, alkenylenyl, or alkynylenyl; W = CO2H; X = a single bond, O, OSO2, SO3, (un)substituted amino(thio)carboxy, (thio)carbamato, (thio)carbamoyloxy, (oxy)amino(thio)carbonyl, (amino)(thio)carbamoyl, aminosulfonyl, or sulfonamido; Y = (un)substituted Ar(Ar); Ar = aromatic ring; ring Z = (un)substituted Ar] and salts, esters, and hydrates thereof are prepared as PPAR (peroxisome proliferator-activated receptor) agonists for the treatment of hyperglycemia, hyperlipemia, and inflammatory diseases. For example, the acid II was prepared in a multi-step synthesis starting from 2-chloro-4-propoxybenzoic acid and the corresponding amine (prepn given) in DMF in the presence of Et3N and di-Et cyanophosphonate. II showed EC50 of 0.013, 0.038, and 0.005 μM against PPAR α, PPAR β, and PPAR γ, resp.

IT 499788-79-3P 499788-88-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(PPAR agonist; prepn. of benzyltetrahydrofurancarboxylic acid derivs. as PPAR agonists for treatment of hyperglycemia, hyperlipemia, and inflammatory diseases)

RN 499788-79-3 CAPLUS
CN 2-Furancarboxylic acid, 2-[[3-[(2R)-3-[2-(2-benzoxazolyl)phenoxy]-2-hydroxypropoxy]phenyl]methyl]tetrahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 499788-88-4 CAPLUS
CN 2-Furancarboxylic acid, 2-[[3-[(2R)-3-[[2-(4-cyanophenyl)-5-benzoxazolyl]oxy]-2-hydroxypropoxy]phenyl]methyl]tetrahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 10 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1999:710182 CAPLUS
DOCUMENT NUMBER: 132:36376
TITLE: Synthesis of liquid crystalline monomers and side-chain polymers containing 2-phenylbenzoxazole in mesogenic unit
AUTHOR(S): Kim, Sehoon; Sohn, Jiwon; Park, Soo Young
CORPORATE SOURCE: Dept. of Fiber and Polymer Science, Seoul National University, Seoul, 151-742, S. Korea
SOURCE: Bulletin of the Korean Chemical Society (1999), 20(4), 473-477
CODEN: BKCSDE; ISSN: 0253-2964
PUBLISHER: Korean Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Direct cyclization between 2-aminophenol part and benzaldehyde counterpart in the presence of lead acetate gave hydroxy-substituted 2-phenylbenzoxazole. From the obtained benzoxazole derivs., benzoxazole-based fluorescent monomers and polymers were prepared and their liquid crystallinity was confirmed.

IT 252235-45-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and characterization of)

RN 252235-45-3 CAPLUS
CN Benzoic acid, 4-[[6-[(2-methyl-1-oxo-2-propenyl)oxy]hexyl]oxy]-, 4-[6-[(2S)-2-methylbutoxy]-2-benzoxazolyl]phenyl ester, homopolymer (9CI) (CA INDEX NAME)

CM 1

CRN 252235-41-9
CMF C35 H39 N O7

Absolute stereochemistry.

PAGE 1-A



L10 ANSWER 10 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B



IT 252235-41-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and polymerization of liquid crystalline monomers containing phenylbenzoxazole)

RN 252235-41-9 CAPLUS
CN Benzoic acid, 4-[[6-[(2-methyl-1-oxo-2-propenyl)oxy]hexyl]oxy]-, 4-[6-[(2S)-2-methylbutoxy]-2-benzoxazolyl]phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1998:278518 CAPLUS
DOCUMENT NUMBER: 128:321542
TITLE: A novel histamine 2(H2) receptor antagonist with gastroprotective activity. I. Synthesis and pharmacological evaluation of N-phenoxypropylacetamide derivatives with thioether function
AUTHOR(S): Sekine, Yasuo; Hirakawa, Nobuhiko; Kashiwaba, Noriaki; Matsumoto, Hajime; Kutsuma, Teruo; Yamaura, Tetsuaki; Sekine, Akihiko
CORPORATE SOURCE: Pharm. Res. Lab., Fujirebio Inc., Tokyo, 192-0031, Japan
SOURCE: Chemical & Pharmaceutical Bulletin (1998), 46(4), 610-615
CODEN: CPBTAL; ISSN: 0009-2363
PUBLISHER: Pharmaceutical Society of Japan
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 128:321542
GI



AB In an attempt to develop new types of anti-ulcer agents, a series of N-(phenoxypropyl)acetamide derivs. with a thioether moiety, I (R = 4-pyridyl, Ph, 2-naphthyl, etc., m = 1, 3, 5, n = 0, 1, 3, 5, p = 0, 1, 2), and their sulfur-oxidized analogs were synthesized and evaluated for histamine H2-receptor antagonistic activity, Ca antagonistic activity and gastric anti-secretory activity in the lumen-perfused rat. Selected compds. were also tested for gastroprotective activity, which was expected to be based on Ca antagonistic activity. Structure-activity relationships are discussed. As a thioether moiety, -CH2-S(O)p-CH2-Ar (Ar; Ph or furyl) was found to be optimal for the above activities. Especially, N-[3-[(3-piperidinomethyl)phenoxy]propyl]acetamide with a benzyl sulfinyl, benzylsulfonyl, furfurylsulfinyl or furfurylsulfonyl group showed potent gastroprotective activity upon oral administration in a rat model. These compds. are candidates for novel anti-ulcer drugs with gastric anti-secretory and gastroprotective activities. 2-Furfurylsulfinyl-N-(3-[(piperidinomethyl)phenoxy]propyl]-acetamide was the most potent among the compds. tested and was given the code designation FRG-8701.
IT 207221-26-9P 207221-27-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological

L10 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn., antihistaminic, and structure activity relationship of N-(phenoxypropyl)acetamide thioether derivs.)
RN 207221-26-9 CAPLUS
CN Acetamide, 2-[[[4-(2-benzothiazolyl)phenyl]methyl]thio]-N-[3-[3-(1-piperidinylmethyl)phenoxy]propyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

RN 207221-27-0 CAPLUS
CN Acetamide, 2-[[4-(2-benzothiazolyl)phenyl]methoxy]-N-[3-[3-(1-piperidinylmethyl)phenoxy]propyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1994:325759 CAPLUS
DOCUMENT NUMBER: 120:325759
TITLE: Dichroic disazo dyes and light-polarizing films containing the same
INVENTOR(S): Misawa, Tsutayoshi; Ogiso, Akira; Ito, Naoto; Imai, Rihoko
PATENT ASSIGNEE(S): Mitsui Toatsu Chemicals, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 8 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 05320530	A	19931203	JP 1992-127056	19920520
JP 3100461	B2	20001016		
PRIORITY APPLN. INFO.:			JP 1992-127056	19920520

OTHER SOURCE(S): MARPAT 120:325759
GI





AB The title dyes that can be used with hydrophobic resins have the general formula I [R1 = H, Me, OH, Cl; R2, R3 = (un)substituted C1-3 alkyl, or R2R3 = ring members]. Q(NH2)2 (5-bonding) was tetrazotized and coupled with PhNMe2 to give the corresponding I, which was used in a biaxially stretched PET film (100 μm thickness) with polarization (475 nm) 99.5%, storability (80°, 90%RH) ≥500 h, and good dimensional stability.
IT 155582-06-2P 155582-15-3P
RL: PREP (Preparation)
(manufacture of dichroic, manufacture of, for PET polarizing films)
RN 155582-06-2 CAPLUS
CN Propanenitrile, 3-[[4-[[4-[2-[4-[6-[2-[4-[[4-[(2-cyanoethyl)ethylamino]phenyl]azo]phenyl]ethenyl]-2-benzoxazolyl]phenyl]ethenyl]phenyl]azo]phenyl]ethylamino]- (9CI) (CA INDEX NAME)

L10 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 155582-15-3 CAPLUS
CN Propanenitrile, 3-[[4-[[4-[2-[4-[5-[2-[4-[[4-[(2-cyanoethyl)ethylamino]phenyl]azo]phenyl]ethenyl]-2-benzoxazolyl]phenyl]ethenyl]phenyl]azo]phenyl]ethylamino]- (9CI) (CA INDEX NAME)

PAGE 1-A



L10 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B



L10 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1993:495398 CAPLUS
DOCUMENT NUMBER: 119:95398
TITLE: Synthesis and acaricidal activity of novel fluorinated benzothiazolyl pyrethroids
AUTHOR(S): Chen, Guangming; Chen, Fuheng
CORPORATE SOURCE: Dep. Appl. Chem., Beijing Agric. Univ., Beijing, 100094, Peop. Rep. China
SOURCE: Pesticide Science (1992), 36(3), 233-7
CODEN: PSSCBG; ISSN: 0031-613X
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



AB A series of novel pyrethroids I [n = 0, 1; R1 = H, F, CF3; R2 = Q, Q1; R3 = H, CN; R4 = Me, Cl; R5 = Cl, F2CHO] containing a benzothiazole ring which replaces the phenoxy substituent in the benzyl ester portion have been synthesized. The compds. prepared were from four types of acid substituent, and were screened for acaricidal activity against Tetranychus viennenist. Several compds. showed good activity at 250 mg/L. As expected, it was found that the highest activity was associated with substitution at the 3-position of the benzyl ring. A fluoro- or trifluoromethyl-substituent in the benzothiazole ring usually enhanced potency. α-Cyano substitution also increased activity.

IT 148929-42-4P 148929-46-8P 148929-50-4P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and acaricidal activity of)

RN 148929-42-4 CAPLUS
CN Benzeneacetic acid, 4-(difluoromethoxy)-α-(1-methylethyl)-, [3-(2-benzothiazolyl)phenyl]methyl ester (9CI) (CA INDEX NAME)



RN 148929-46-8 CAPLUS

L10 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN Benzeneacetic acid, 4-(difluoromethoxy)-α-(1-methylethyl)-, [3-(5-fluoro-2-benzothiazolyl)phenyl]methyl ester (9CI) (CA INDEX NAME)



RN 148929-50-4 CAPLUS
CN Benzeneacetic acid, 4-(difluoromethoxy)-α-(1-methylethyl)-, [3-[5-(trifluoromethyl)-2-benzothiazolyl]phenyl]methyl ester (9CI) (CA INDEX NAME)



L10 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1993:38913 CAPLUS
DOCUMENT NUMBER: 118:38913
TITLE: Preparation of benzoxazoles and dihydrobenzofuran derivatives as cholesterol acyltransferase inhibitors
INVENTOR(S): Shiota, Tatsuki; Takeyasu, Takumi; Mochizuki, Tsutomu; Kataoka, Kenichiro; Tanabe, Hirofumi; Ota, Mikio; Kano, Masatoshi; Yamaguchi, Hisao
PATENT ASSIGNEE(S): Teijin Ltd., Japan
SOURCE: PCT Int. Appl., 125 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9212144	A1	19920723	WO 1991-JP1793	19911227
W: AU, CA, HU, JP, KR, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, IT, NL, SE				
AU 9191105	A	19920817	AU 1991-91105	19911227
AU 652981	B2	19940915		
EP 632031	A1	19950104	EP 1992-901873	19911227
EP 632031	B1	20000503		
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE				
HU 68721	A2	19950728	HU 1993-1866	19911227
AT 192446	T	20000515	AT 1992-901873	19911227
ES 2145743	T3	20000716	ES 1992-901873	19911227
JP 3095413	B2	20001003	JP 1992-501774	19911227
US 5496853	A	19960305	US 1995-429023	19950426
PRIORITY APPLN. INFO.:			JP 1990-415443 A	19901228
			JP 1991-29143 A	19910131
			WO 1991-JP1793 A	19911227
			US 1993-78274 B1	19930622

OTHER SOURCE(S): MARPAT 118:38913
GI

L10 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



AB The title compds. [I, II; R1 = (substituted) cycloalkyl, cycloalkenyl, etc.; R2 = H, C2-8.alkyl; R4 = H, C1-20 alkyl, alkenyl, alkynyl, etc., R5-R8 = H, C1-20 alkyl, R5R6 or R7R8 form 5-7-membered carbocycle; n = 0, 1; P, Q, R = H, halo, NH2, NO2, cyano, CO2H, OH, C1-20 alkyl etc.], useful in treating hyperlipemia and arteriosclerosis, are prepared Stirring a mixture of 51 mg amino compound III (preparation given) and 65 mg 1-decylcyclopentarecarbonyl chloride in CH2Cl2 containing Et3N at room temperature gave 35 mg amide IV, which showed IC50 of 8.3 + 10-7M against cholesterol acyltransferase.
IT 144983-51-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as anticholesteremic agent)
RN 144983-51-7 CAPLUS
CN Hexanamide, 6-[4-(1,1-dimethylethyl)phenoxy]-N-(5,6-dimethyl-2-phenyl-7-benzoxazolyl)-2,2-dimethyl- (9CI) (CA INDEX NAME)

L10 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L10 ANSWER 15 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1992:470556 CAPLUS
DOCUMENT NUMBER: 117:70556
TITLE: Nucleophilic displacement method for synthesis of non-rigid polybenzoxazoles or polybenzimidazoles or polybenzothiazoles
INVENTOR(S): Inbasekaran, Muthiah N.; Mullins, Michael J.
PATENT ASSIGNEE(S): Dow Chemical Co., USA
SOURCE: U.S., 16 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5104960	A	19920414	US 1989-313936	19890222
US 5194562	A	19930316	US 1992-819419	19920110
US 5216110	A	19930601	US 1992-819421	19920110
WO 9314071	A1	19930722	WO 1992-US165	19920110
W: CA, JP, KR				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE				
EP 623115	A1	19941109	EP 1992-906156	19920110
R: BE, DE, FR, GB, IT, NL				
PRIORITY APPLN. INFO.:			US 1989-313936 A3	19890222
			WO 1992-US165 W	19920110

AB The title polymers are prepared by contacting an azole-containing compound (bearing an azole ring, a 2-position-bonded aryl group, and an activated leaving group) and a displacing compound (bearing an inert non-electron-withdrawing group linked to a N-containing nucleophilic group and a removable counter moiety to the nucleophilic group). 2-(4-Fluorophenyl)-6-(trimethylsilylether)benzoxazole was polymerized in the presence of Ph2SO2, PhCl, and CsF catalyst to give a polymer with with 1% weight loss at 514°.
IT 142629-49-0P
RL: RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
(preparation and polymerization of)
RN 142629-49-0 CAPLUS
CN Pentanedioic acid, bis[2-(4-fluorophenyl)-6-benzoxazolyl] ester (9CI) (CA INDEX NAME)



IT 142630-05-5P 142675-48-7P
RL: PREP (Preparation)
(preparation of, heat-resistant)
RN 142630-05-5 CAPLUS
CN Poly[2,6-benzoxazolediyloxy(1,5-dioxo-1,5-pentanediyl)oxy-6,2-

L10 ANSWER 15 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
benzoxazolediyl-1,4-phenyleneoxy-1,4-phenylene(1-methylethylidene)-1,4-phenyleneoxy-1,4-phenylene] (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 142675-48-7 CAPLUS
CN Pentanedioic acid, bis[2-(4-fluorophenyl)-6-benzoxazolyl] ester, polymer with 4,4'-(1-methylethylidene)bis[phenol] (9CI) (CA INDEX NAME)

CM 1

CRN 142629-49-0
CMF C31 H20 F2 N2 O6



L10 ANSWER 15 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CM 2

CRN 80-05-7
CMF C15 H16 O2



L10 ANSWER 16 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1991:690754 CAPLUS
DOCUMENT NUMBER: 115:290754
TITLE: Side chain polymers exhibiting nonlinear optical response and devices employing them
INVENTOR(S): Allen, Diane E.; Demartino, Ronald N.
PATENT ASSIGNEE(S): Hoechst Celanese Corp., USA
SOURCE: U.S., 11 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4978476	A	19901218	US 1990-504193	19900402
PRIORITY APPLN. INFO.:			US 1990-504193	19900402

GI



I



II

AB The title polymers are described by the general formulas I and II (R = H or C1-4 alkyl; R1 = C1-6 alkyl; m, m1, m2, n are integers; m ≥ 5; m1 + m2 ≥ 10; 4n = 1-20; X = S, O, or NR; Z = H, CN, NO2, or CH3). Optical devices (light switches, modulators, and frequency doublers) employing the polymers, which may exhibit 2nd and 3rd order nonlinear susceptibilities.

IT 136775-85-4P 136775-93-4P 137667-47-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, in nonlinear optical material preparation)

RN 136775-85-4 CAPLUS

L10 ANSWER 16 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN 2-Propenoic acid, 2-methyl-, 4-[[4-[2-[4-(2-benzoxazolyl)phenyl]ethenyl]phenyl]methylamino]butyl ester (9CI) (CA INDEX NAME)



RN 136775-93-4 CAPLUS
CN 2-Propenoic acid, 2-methyl-, 2-[methyl[4-[2-[4-(5-nitro-2-benzothiazolyl)phenyl]ethenyl]phenyl]amino]ethyl ester (9CI) (CA INDEX NAME)



RN 137667-47-1 CAPLUS
CN 2-Propenoic acid, 2-methyl-, 4-[[4-[2-[4-(2-benzoxazolyl)phenyl]ethenyl]phenyl]methylamino]butyl ester, homopolymer (9CI) (CA INDEX NAME)

CM 1

CRN 136775-85-4
CMF C30 H30 N2 O3



IT 137667-44-8P 137667-45-9P 137691-08-8P
RL: PREP (Preparation)
(preparation of, as nonlinear optical material)

RN 137667-44-8 CAPLUS
CN 2-Propenoic acid, 2-methyl-, 2-[methyl[4-[2-[4-(5-nitro-2-benzothiazolyl)phenyl]ethenyl]phenyl]amino]ethyl ester, homopolymer (9CI) (CA INDEX NAME)

CM 1

CRN 136775-93-4
CMF C28 H25 N3 O4 S

L10 ANSWER 16 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 137667-45-9 CAPLUS
CN 2-Propenoic acid, 2-methyl-, 4-[[4-[2-[4-(2-benzoxazolyl)phenyl]ethenyl]phenyl]methylamino]butyl ester, polymer with ethyl 2-methyl-2-propenoate (9CI) (CA INDEX NAME)

CM 1

CRN 136775-85-4
CMF C30 H30 N2 O3



CM 2

CRN 97-63-2
CMF C6 H10 O2



RN 137691-08-8 CAPLUS
CN 2-Propenoic acid, 2-methyl-, 2-[methyl[4-[2-[4-(5-nitro-2-benzothiazolyl)phenyl]ethenyl]phenyl]amino]ethyl ester, polymer with 2-propenoic acid (9CI) (CA INDEX NAME)

CM 1

CRN 136775-93-4
CMF C28 H25 N3 O4 S

L10 ANSWER 16 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



CM 2

CRN 79-10-7
CMF C3 H4 O2